Pathological factors evaluating prostate cancer

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10201/27658

RefMan EndNote BibTex RefWorks Excel CSV PDF Mendeley

Registro completo de metadatos

Campo DC	Valor	Lengua/Idioma
dc.contributor.author	Yu, Y.P.	es
dc.contributor.author	Luo, J.H.	es
dc.date.accessioned	2012-05-21T12:11:29Z	-
dc.date.available	2012-05-21T12:11:29Z	-
dc.date.issued	2007	-
dc.identifier.issn	0213-3911	es
dc.identifier.uri	http://hdl.handle.net/10201/27658	-
dc.description.abstract	Prostate cancer is one of the most prevalent malignancies for men world wide. However, only a small fraction of prostate cancer cases are metastasizing and life-threatening. Even though the detection rate of prostate cancer has been steadily increased in the last two decades due to implementation of PSA screening, it is still not clear what factors govern its clinical outcomes. In this review, we will discuss several recent pathological advances that might contribute to the progression of prostate cancer. In addition, this review will cover a brief overview on conventional morphological evaluation of prostate cancer differentiation	es
dc.format	application/pdf	es
dc.format.extent	10	es
dc.language	eng	es
dc.publisher	Murcia : F. Hernández	es
dc.relation.ispartof	Histology and histopathology	es
dc.rights	info:eu-repo/semantics/openAccess	es
dc.subject	Androgen receptor	es
dc.subject	Hepsin	es
dc.subject.other	616 - Patología. Medicina clínica. Oncología	es
dc.title	Pathological factors evaluating prostate cancer	es
dc.type	info:eu-repo/semantics/article	es
Aparece en las colecciones:	Vol.22, nº11 (2007)

Ficheros en este ítem:

Fichero	Descripción	Tamaño	Formato
Pathological factors evaluating prostate cancer.pdf		268,53 kB	Adobe PDF	Visualizar/Abrir